These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

734 related articles for article (PubMed ID: 37536040)

  • 21. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
    Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
    Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PGAM1 suppression remodels the tumor microenvironment in triple-negative breast cancer and synergizes with anti-PD-1 immunotherapy.
    Zhang D; Wang M; Wang W; Ma S; Yu W; Ren X; Sun Q
    J Leukoc Biol; 2024 Sep; 116(3):579-588. PubMed ID: 38478709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while TGF-β receptor plus dual checkpoint inhibition maintains antitumor immune cells.
    Rana M; Kansal R; Chaib M; Teng B; Morrrison M; Hayes DN; Stanfill AG; Shibata D; Carson JA; Makowski L; Glazer ES
    Mol Carcinog; 2022 Jun; 61(6):549-557. PubMed ID: 35319799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment.
    Yang M; Li J; Gu P; Fan X
    Bioact Mater; 2021 Jul; 6(7):1973-1987. PubMed ID: 33426371
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
    Abe S; Nagata H; Crosby EJ; Inoue Y; Kaneko K; Liu CX; Yang X; Wang T; Acharya CR; Agarwal P; Snyder J; Gwin W; Morse MA; Zhong P; Lyerly HK; Osada T
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35039461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
    Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
    Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer.
    Li X; Tang L; Chen Q; Cheng X; Liu Y; Wang C; Zhu C; Xu K; Gao F; Huang J; Wang R; Guan X
    Chin Med J (Engl); 2022 Oct; 135(20):2436-2445. PubMed ID: 36583862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bio-orthogonal click chemistry strategy for PD-L1-targeted imaging and pyroptosis-mediated chemo-immunotherapy of triple-negative breast cancer.
    Wang Y; Chen Y; Ji DK; Huang Y; Huang W; Dong X; Yao D; Wang D
    J Nanobiotechnology; 2024 Aug; 22(1):461. PubMed ID: 39090622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Novel TGF-β-Related Signature for Predicting Prognosis, Tumor Microenvironment, and Therapeutic Response in Colorectal Cancer.
    Tao B; Yi C; Ma Y; Li Y; Zhang B; Geng Y; Chen Z; Ma X; Chen J
    Biochem Genet; 2024 Aug; 62(4):2999-3029. PubMed ID: 38062276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
    Sow HS; Ren J; Camps M; Ossendorp F; Ten Dijke P
    Cells; 2019 Apr; 8(4):. PubMed ID: 30959852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting therapy and tumor microenvironment remodeling of triple-negative breast cancer by ginsenoside Rg3 based liposomes.
    Xia J; Zhang S; Zhang R; Wang A; Zhu Y; Dong M; Ma S; Hong C; Liu S; Wang D; Wang J
    J Nanobiotechnology; 2022 Sep; 20(1):414. PubMed ID: 36109762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biomimetic black phosphorus quantum dots-based photothermal therapy combined with anti-PD-L1 treatment inhibits recurrence and metastasis in triple-negative breast cancer.
    Zhao P; Xu Y; Ji W; Zhou S; Li L; Qiu L; Qian Z; Wang X; Zhang H
    J Nanobiotechnology; 2021 Jun; 19(1):181. PubMed ID: 34120612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy.
    Yang Z; Sun JK; Lee MM; Chan MK
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunomodulator-Mediated Suppressive Tumor Immune Microenvironment Remodeling Nanoplatform for Enhanced Immuno/Chemo/Photothermal Combination Therapy of Triple Negative Breast Cancer.
    Wang A; Yang X; Li R; Shao L; Zhao W; Hu X; Fang K; Chai K; Shi S; Dong C
    ACS Appl Mater Interfaces; 2023 Nov; 15(46):53318-53332. PubMed ID: 37943829
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression.
    Kim M; Lee JS; Kim W; Lee JH; Jun BH; Kim KS; Kim DE
    J Control Release; 2022 Aug; 348():893-910. PubMed ID: 35760233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic efficacy and mechanism of CD73-TGFβ dual-blockade in a mouse model of triple-negative breast cancer.
    Xing Y; Ren ZQ; Jin R; Liu L; Pei JP; Yu K
    Acta Pharmacol Sin; 2022 Sep; 43(9):2410-2418. PubMed ID: 35082394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A hierarchical tumor-targeting strategy for eliciting potent antitumor immunity against triple negative breast cancer.
    Lin M; Cai Y; Chen G; Zhong H; Li B; Li T; Xiao Z; Shuai X
    Biomaterials; 2023 May; 296():122067. PubMed ID: 36854221
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of a natural small-molecule compound that suppresses tumor EMT, stemness and metastasis by inhibiting TGFβ/BMP signaling in triple-negative breast cancer.
    Di L; Liu LJ; Yan YM; Fu R; Li Y; Xu Y; Cheng YX; Wu ZQ
    J Exp Clin Cancer Res; 2019 Mar; 38(1):134. PubMed ID: 30898152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biomimetic "nano-spears" for CAFs-targeting: splintered three "shields" with enhanced cisplatin anti-TNBC efficiency.
    Wu Y; Chen R; Ni S; Hu K
    J Control Release; 2024 Jun; 370():556-569. PubMed ID: 38697316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.
    Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K
    J Hematol Oncol; 2022 Oct; 15(1):142. PubMed ID: 36209176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.